Citi upgrades Zymeworks to Buy on valuation. Citi analyst Yigal Nochomovitz upgraded to Buy from Neutral and raised his price target for the shares to $20 from $19. The company is well capitalized following the June offering with a cash runway expected to last through at least one planned Phase 2/3 registrational study for ZW-25, Nochomovitz tells investors in a research note. The analyst cites valuation for his upgrade to Buy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.